![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MYO3B |
Gene summary for MYO3B |
![]() |
Gene information | Species | Human | Gene symbol | MYO3B | Gene ID | 140469 |
Gene name | myosin IIIB | |
Gene Alias | MYO3B | |
Cytomap | 2q31.1 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | B7ZM71 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
140469 | MYO3B | HCC1 | Human | Liver | HCC | 5.93e-05 | 4.79e-01 | 0.5336 |
140469 | MYO3B | HCC2 | Human | Liver | HCC | 2.79e-23 | 1.46e+00 | 0.5341 |
140469 | MYO3B | HCC5 | Human | Liver | HCC | 3.79e-24 | 1.17e+00 | 0.4932 |
140469 | MYO3B | RNA-P17T-P17T-4 | Human | Lung | IAC | 4.28e-05 | 6.88e-01 | 0.343 |
140469 | MYO3B | RNA-P3T-P3T-1 | Human | Lung | IAC | 1.02e-16 | 9.33e-01 | 0.1829 |
140469 | MYO3B | RNA-P3T-P3T-2 | Human | Lung | IAC | 4.73e-12 | 7.95e-01 | 0.1835 |
140469 | MYO3B | RNA-P3T-P3T-4 | Human | Lung | IAC | 7.47e-20 | 9.82e-01 | 0.1859 |
140469 | MYO3B | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 4.64e-16 | 5.44e-01 | -0.0166 |
140469 | MYO3B | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 5.18e-16 | 4.97e-01 | -0.0132 |
140469 | MYO3B | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 8.04e-21 | 5.82e-01 | -0.013 |
140469 | MYO3B | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 9.48e-21 | 6.37e-01 | -0.0121 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00485684 | Lung | IAC | embryonic organ development | 64/2061 | 427/18723 | 6.46e-03 | 4.59e-02 | 64 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MYO3B | SNV | Missense_Mutation | novel | c.1111N>A | p.Leu371Ile | p.L371I | Q8WXR4 | protein_coding | tolerated(0.09) | benign(0.098) | TCGA-21-1081-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
MYO3B | SNV | Missense_Mutation | rs771451504 | c.1069N>C | p.Asp357His | p.D357H | Q8WXR4 | protein_coding | deleterious(0.01) | benign(0.248) | TCGA-37-4130-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
MYO3B | SNV | Missense_Mutation | c.677C>G | p.Ala226Gly | p.A226G | Q8WXR4 | protein_coding | deleterious(0.02) | probably_damaging(0.936) | TCGA-39-5027-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
MYO3B | SNV | Missense_Mutation | rs371432418 | c.1711N>A | p.Asp571Asn | p.D571N | Q8WXR4 | protein_coding | deleterious(0.04) | benign(0.178) | TCGA-56-8504-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
MYO3B | SNV | Missense_Mutation | rs370443836 | c.3422N>T | p.Thr1141Met | p.T1141M | Q8WXR4 | protein_coding | tolerated_low_confidence(0.2) | benign(0) | TCGA-63-A5MU-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | PD |
MYO3B | SNV | Missense_Mutation | c.1265N>T | p.Cys422Phe | p.C422F | Q8WXR4 | protein_coding | deleterious(0.04) | benign(0.021) | TCGA-66-2763-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
MYO3B | SNV | Missense_Mutation | novel | c.3928N>C | p.Ser1310Pro | p.S1310P | Q8WXR4 | protein_coding | tolerated_low_confidence(0.33) | benign(0.143) | TCGA-77-7139-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
MYO3B | SNV | Missense_Mutation | novel | c.884N>T | p.Gly295Val | p.G295V | Q8WXR4 | protein_coding | tolerated(0.05) | benign(0.001) | TCGA-77-7141-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
MYO3B | SNV | Missense_Mutation | novel | c.1105G>A | p.Asp369Asn | p.D369N | Q8WXR4 | protein_coding | tolerated(0.23) | benign(0.038) | TCGA-77-8008-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
MYO3B | SNV | Missense_Mutation | novel | c.1504N>A | p.Pro502Thr | p.P502T | Q8WXR4 | protein_coding | tolerated(0.25) | benign(0.405) | TCGA-85-A511-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |